Tapimmune Inc., of Jacksonville, Fla., said phase I data published in Clinical Cancer Research showed that TPIV-200, its multi-epitope T-cell vaccine targeting folate receptor alpha (FRa), in patients with ovarian and breast cancer showed safety and long-lasting immune responses.